FDA Grants Approves Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

$FDA Grants Approves Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma$

On June 26, the US Food and Drug Administration (FDA) granted accelerated approval to epcoritamab-bysp, a bispecific CD20-directed CD3 T-cell engager, for adult patients with relapsed or refractory follicular lymphoma after 2 or more lines of systemic therapy.

For more information read the FDA announcement and the Genmab Inc. announcement.

Posted 6/27/2024